<description>&lt;p&gt;It's estimated that as many as 10 per cent of adults in Canada use a GLP-1 type drug like Ozempic. The prescription medicine is used for type 2 diabetes management and increasingly prescribed off-label for weight loss. And this month, for the first time, the World Health Organization has conditionally recommended GLP-1 drugs for the long-term treatment of obesity.&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;But while these drugs have been called a game-changing tool to manage a complex and stigmatized health condition, there’s also a lot of questions about the potential negative impact.&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;With Ozempic’s patent set to expire soon in Canada, and more affordable generic options about to hit the market, a lot more people you know could end up on a weight-loss drug.&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;Today we bring you the rise and risks of GLP-1s with help from Dylan Scott. He is a Senior Correspondent at Vox who covers health.&lt;/p&gt;&lt;p&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;For transcripts of Front Burner, please visit:&amp;nbsp;&lt;a href="https://www.cbc.ca/radio/frontburner/transcripts" rel="noopener noreferrer" target="_blank"&gt;https://www.cbc.ca/radio/frontburner/transcripts&lt;/a&gt;&lt;/p&gt;</description>

It's estimated that as many as 10 per cent of adults in Canada use a GLP-1 type drug like Ozempic. The prescription medicine is used for type 2 diabetes management and increasingly prescribed off-label for weight loss. And this month, for the first time, the World Health Organization has conditionally recommended GLP-1 drugs for the long-term treatment of obesity. But while these drugs have been called a game-changing tool to manage a complex and stigmatized health condition, there’s also a lot of questions about the potential negative impact. With Ozempic’s patent set to expire soon in Canada, and more affordable generic options about to hit the market, a lot more people you know could end up on a weight-loss drug. Today we bring you the rise and risks of GLP-1s with help from Dylan Scott. He is a Senior Correspondent at Vox who covers health. For transcripts of Front Burner, please visit:&nbsp;<a href="https://www.cbc.ca/radio/frontburner/transcripts" rel="noopener noreferrer" target="_blank">https://www.cbc.ca/radio/frontburner/transcripts</a>

Front Burner

Should everybody be taking Ozempic?

Should everybody be taking Ozempic?

Description